[Skip to Content]
[Skip to Content Landing]
Views 244
Citations 0
Comment & Response
March 2017

Controversies in Using Off-Label Intravitreous Bevacizumab for Patients With Diabetic Macular Edema

Author Affiliations
  • 1Health Technology Assessment Unit, Ente di Supporto Tecnico Amministrativo Regionale, Regional Health Service, 50100 Firenze, Italy
JAMA Ophthalmol. 2017;135(3):290-291. doi:10.1001/jamaophthalmol.2016.5674

To the Editor Based on the results of the Diabetic Retinopathy Clinical Research Network Comparative Effectiveness Trial, Ross and colleagues1 have conducted a pharmacoeconomic study in which the cost-effectiveness of aflibercept, ranibizumab, and off-label bevacizumab was estimated for patients with diabetic macular edema. Defining the place in therapy for these treatments took into account that off-label bevacizumab costs 31 and 20 times less than aflibercept and ranibizumab, respectively, while differences in efficacy are modest.

First Page Preview View Large
First page PDF preview
First page PDF preview